References
- Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant. 2005;35(2):107–119.
- Reibke R, Dick A, Hubmann M, et al. Monitoring of bone marrow chimerism after allogeneic hematopoietic stem cell transplantation – evaluation of a qPCR based chimerism assay. Blood. 2014;124(21):3866–3866.
- Preuner S, Lion T. Post-transplant monitoring of chimerism by lineage-specific analysis. In: Beksaç M, editor. Bone marrow and stem cell transplantation. New York: Springer; 2014. p. 271–291.
- Reshef R, Hexner EO, Loren AW, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014;20(11):1758–1766.
- Serrano J, Roman J, Sanchez J, et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 BCR-ABL and p190 BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 BCR-ABL detection precede cytogenetic relapse. Blood. 2000;95(8):2659–2665.
- Jain T, Kunze KL, Mountjoy L, et al. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020;10(3):36.
- Pérez-Simón JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16(8):1423–1431.
- Caldemeyer LE, Akard LP, Edwards JR, et al. Donor lymphocyte infusions used to treat mixed-chimeric and high-risk patient populations in the relapsed and nonrelapsed settings after allogeneic transplantation for hematologic malignancies are associated with high five-year survival if persistent full donor chimerism is obtained or maintained. Biol Blood Marrow Transplant. 2017;23(11):1989–1997.
- Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015;21(2):288–292.
- Lamba R, Abella E, Kukuruga D, et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia. 2004;18(10):1681–1686.
- van Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009;50(11):1809–1817.
- Lim ZY, Pearce L, Ingram W, et al. Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transplant. 2008;41(6):587–588.
- Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001;7(9):473–485.
- Centers for Medicare and Medicaid Services: Clinical Laboratory Fee Schedule; 2020. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched
- Tang X, Alatrash G, Ning J, et al. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014;20(8):1139–1144.